Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01663857 · ClinicalTrials.gov registry record · Phase 1
A Study LY2228820 for Recurrent Ovarian Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT01663857: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT01663857 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 118 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01663857, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.
Primary Outcome
Recommended Phase 2 dose of LY2228820 that could be safely administered in combination with gemcitabine and carboplatin based on defined dose limiting toxicities (DLT) assessment and MTD definition. The MTD is defined as the highest dose level at which no more than 33% of patients experience a DLT during Cycle 1 that does not exceed the single-agent MTD for LY2228820 (300 mg Q12H).
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Gemcitabine
- DRUG LY2228820
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2012-07 |
| Est. Completion | 2018-05-11 |
| Phase | Phase 1 |
What the finished NCT01663857 record still lists
NCT01663857 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher).
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01663857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01663857 about?
NCT01663857 is a clinical study titled "A Study LY2228820 for Recurrent Ovarian Cancer". A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.
What is the current status of trial NCT01663857?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2012-07. Estimated completion is 2018-05-11.
What interventions are being tested in trial NCT01663857?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Gemcitabine (DRUG), LY2228820 (DRUG).
Who is sponsoring clinical trial NCT01663857?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01663857's enrollment target sits among peer trials
118 499th of 2000 higher than 1,502 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia